TFmed 2026 features a dynamic, transdisciplinary four-day program focused on proxidrugs (e.g., PROTACs and molecular glues), nucleic acid-based strategies (mRNA and antisense technologies), and cell therapies, with applications across cardiology, diabetes, ageing, inflammation, infection, cancer and neurodegeneration.

Registration is open until 16th January.